A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Clinical trial NCT07365319 · RECRUITING

Trial details

NCT number: NCT07365319
Sponsor: Eikon Therapeutics
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer (Squamous or Non Squamous)Stage 4 NSCLC

Start date: 2026-06-15
Primary completion: 2035-12-31
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.